DeepMed Research

PRIMUS PHARMACEUTICALS

🇮🇳India

Country: 🇮🇳India

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

DFD01 Spray HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis

Phase 3

Terminated

Conditions: Plaque Psoriasis

Interventions: Drug: DFD01 Spray

First Posted Date: 2015-08-19

Last Posted Date: 2024-03-07

Lead Sponsor: Primus Pharmaceuticals

Target Recruit Count: 3

Registration Number: NCT02527421

Locations: 🇺🇸
Site 102, Encino, California, United States
🇺🇸
Site 101, Houston, Texas, United States
🇺🇸
Site 104, Irvine, California, United States

and more 5 locations

Safety and Efficacy of Vasculera® in the Healing of Diabetic Skin Ulcers

Not Applicable

Withdrawn

Conditions: Diabetic Ulcers

Interventions: Dietary Supplement: Vasculera

First Posted Date: 2015-02-11

Last Posted Date: 2024-04-19

Lead Sponsor: Primus Pharmaceuticals

Registration Number: NCT02361437

Locations: 🇺🇸
Nix Hospital, San Antonio, Texas, United States

DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis

Phase 2

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Comp01 Lotion
Drug: DFD01 Spray

First Posted Date: 2014-02-25

Last Posted Date: 2024-03-07

Lead Sponsor: Primus Pharmaceuticals

Target Recruit Count: 75

Registration Number: NCT02070965

Locations: 🇺🇸
California Dermatology and Clinical Research Institute, Encinitas, California, United States
🇺🇸
Redwood Dermatology Research, Santa Rosa, California, United States
🇺🇸
Dermatology Consulting Services, High Point, North Carolina, United States

and more 9 locations

A Comparison of DFD01 Spray Versus Vehicle Spray in Subjects With Moderate Psoriasis

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: DFD01 Spray
Drug: Vehicle Spray

First Posted Date: 2013-10-22

Last Posted Date: 2024-03-07

Lead Sponsor: Primus Pharmaceuticals

Target Recruit Count: 277

Registration Number: NCT01967069

Locations: 🇺🇸
Hudson Dermatology/Clinical Research Advantage, Tempe, Arizona, United States
🇺🇸
Augusta Centre for Dermatology and Skin Renewal, LLC, Augusta, Georgia, United States
🇺🇸
Grekin Skin Institute, Warren, Michigan, United States

and more 25 locations

A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: Vehicle Lotion
Drug: Vehicle Spray
Drug: DFD01 Spray
Drug: Comp01 Lotion

First Posted Date: 2013-09-20

Last Posted Date: 2024-03-07

Lead Sponsor: Primus Pharmaceuticals

Target Recruit Count: 394

Registration Number: NCT01947491

Locations: 🇺🇸
Rivergate Dermatology Clinical Research Center, PLLC, Goodlettsville, Tennessee, United States
🇺🇸
The Center for Skin Research, Houston, Texas, United States
🇺🇸
Skin Surgery Medical Group, Inc., San Diego, California, United States

and more 37 locations

Study of Flavocoxid (Limbrel) Versus Naproxen in Subjects With Moderate-Severe Osteoarthritis of the Knee

Not Applicable

Completed

Conditions: Osteoarthritis

Interventions: Other: flavocoxid 250 mg
Dietary Supplement: Flavocoxid 500 mg
Other: Placebo
Drug: Naproxen

First Posted Date: 2009-06-26

Last Posted Date: 2017-12-13

Lead Sponsor: Primus Pharmaceuticals

Target Recruit Count: 350

Registration Number: NCT00928837

Locations: 🇺🇸
Alan Kivitz MD, Duncansville, Pennsylvania, United States

Efficacy of Flavocoxid 500 mg Compared With Naproxen 500 mg in Subjects With Moderate-severe Osteoarthritis of the Knee

Not Applicable

Completed

Conditions: Osteoarthritis of Knee

Interventions: Dietary Supplement: flavocoxid
Drug: Naproxen

First Posted Date: 2008-11-14

Last Posted Date: 2022-11-01

Lead Sponsor: Primus Pharmaceuticals

Target Recruit Count: 223

Registration Number: NCT00790985

Study of Flavocoxid (Limbrel) vs Naproxen in Subjects With Mod-Severe Osteoarthritis of the Knee

Not Applicable

Completed

Conditions: Osteoarthritis

Interventions: Dietary Supplement: flavocoxid 250 mg
Dietary Supplement: flavocoxid 500 mg
Drug: Naproxen

First Posted Date: 2007-02-14

Last Posted Date: 2015-10-21

Lead Sponsor: Primus Pharmaceuticals

Target Recruit Count: 350

Registration Number: NCT00435292

Locations: 🇺🇸
Primus Pharmaceuticals, Inc, Scottsdale, Arizona, United States

Safety, Efficacy and Acceptability of Flavocoxid (Limbrel)A Pilot Study

Not Applicable

Completed

Conditions: Osteoarthritis

Interventions: Dietary Supplement: flavocoxid
Drug: Naproxen

First Posted Date: 2006-03-15

Last Posted Date: 2015-10-21

Lead Sponsor: Primus Pharmaceuticals

Target Recruit Count: 60

Registration Number: NCT00303017

Locations: 🇺🇸
Timothy Truitt MD, Melbourne, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy